Results 151 to 160 of about 15,740 (203)

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients

British Journal of Haematology, Volume 209, Issue 2, Page 793-798, August 2026.
Sari Kytölä, Anu Partanen, Milla E. L. Kuusisto, Sirpa Koskela, Annasofia Holopainen, Ida Vänttinen, Tanja Ruokoranta, Pia Ettala, Johanna Rimpiläinen, Timo Siitonen, Marja Pyörälä, Heikki Kuusanmäki, Mika Kontro   +12 more
wiley   +1 more source

Fixed-time treatment of elderly patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) using hypomethylating agents and venetoclax - a case series. [PDF]

Ann Hematol
Lindemann A, Göckel G, Garcia-Pardillos G.   +2 more
europepmc   +1 more source

Neutropenia and infectious events during off-label treatment with venetoclax in children with malignant disease: a pharmacovigilance analysis of FDA adverse event reporting system reports. [PDF]

Ann Hematol
Muratore E, Giunchi V, Fusaroli M, Baccelli F, Gottardi F, Poluzzi E, Masetti R, Raschi E.   +7 more
europepmc   +1 more source

Clinical Validation of Venetoclax Volumetric Microsampling in Patients with Leukemia with Assessment of Whole-Blood-to-Plasma Conversion Strategies and Self-Microsampling Feasibility. [PDF]

Clin Pharmacokinet
Levens AD, Rijstenbil J, Metscher E, von dem Borne P, Albersen A, Swen JJ, Moes DJAR.   +6 more
europepmc   +1 more source

Successful Treatment of Evans Syndrome Onset With Zanubrutinib in Combination With Romiplostim During Venetoclax Treatment in a Patient With Chronic Lymphocytic Leukemia: A Case Report. [PDF]

Clin Case Rep
Innao V, Barbagallo APM, Bianco O, Leotta V, Consoli U.   +4 more
europepmc   +1 more source

BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease. [PDF]

Blood Adv
Bejarano-García JA, Nufer M, Palacios-Barea MJ, Guijarro-Albaladejo B, Sierro-Martínez B, Bella Á, Robles-Benítez C, García-Guerrero E, Carrasco-Brocal I, Lara-Chica M, Sanoja-Flores L, Mendendez NV, Caballero-Velázquez T, Rodríguez-Gil A, Pérez-Simón JA.   +14 more
europepmc   +1 more source

Morphologic Leukemia-Free State after Venetoclax-Based Therapy in Acute Myeloid Leukemia is Associated with High Relapse Despite Preserved Short-Term Survival. [PDF]

Mediterr J Hematol Infect Dis
Motegi K, Miyao K, Negishi S, Ohara F, Wakabayashi H, Sawa H, Inagaki Y, Sawa M.   +7 more
europepmc   +1 more source

Monomorphic epitheliotropic intestinal T-cell lymphoma presenting as acute small intestinal perforation: a case report and exploratory BCL-2-targeted therapy. [PDF]

Front Med (Lausanne)
He M, Zhou Y, Yao J, Zhang Q, Xu W, Ye X, Cai Y, Liu Z.   +7 more
europepmc   +1 more source

Mechanistic overview and suggested strategies to overcome BCL-2 inhibitor resistance in <i>TP53-</i>mutated acute myeloid leukemia. [PDF]

Front Cell Dev Biol
Iqbal U, Shallis RM.
europepmc   +1 more source

Venetoclax combined with chidamide and decitabine successfully induced remission in relapsed/refractory classical Hodgkin lymphoma: a case report and literature review. [PDF]

Front Immunol
Jin X, Tang Y, Wu Y, Ji J.
europepmc   +1 more source